Find Technologies for Licensing
The localization precision which is limited by the square root of N is obtained due to non-coherent addition of the collected photons. An increase in the precision is required as it leads to significant increase in the imaging resolution for the same amount of illumination of alternatively it allows the same resolution as in conventional…
Read More
Currently, available inexpensive and miniature commercial magnetic sensors exhibit field resolution of hundreds of picotesla and above, while commercial sensors with field resolution of few picotesla and below are normally much larger and more expensive and in some cases operate only at cryogenic temperatures. Namely, there are no commercial magnetic sensors which are miniature and…
Read More
The Problem Immunotherapy has become a revolution in the area of cancer treatment. Compared to the traditional methods, such as invasive surgeries, radiation, and chemotherapy, immunotherapy is more specific and less toxic to patients. Chimeric antigen receptor (CAR)-engineered T cell therapy is considered a promising approach since it has shown remarkable ability to eliminate tumors…
Read More
The Problem In recent years, targeted immune therapies are emerging as standard treatments for advanced-stage cancers. These drugs target cell surface checkpoint proteins to stimulate the recognition and destruction of cancer cells by the immune system. Nevertheless, while the immune checkpoint blockade approach can induce durable responses across multiple types of malignancies, these remarkable responses…
Read More
The Problem HCV is a major public health problem, with over 185 million people infected worldwide and at risk for developing life-threatening liver disease. Although FDA approved several Direct-Acting Antiviral Drugs (DAAs) demonstrating high efficacy and safety, they are highly expensive and unaffordable. Vaccines typically represent the most cost-effective strategy to prevent infectious disease which…
Read More
The Problem De-regulation of Robo receptors appear in a number of diseases and types of cancer and the therapeutic potential for drugs that will modulate Robo activities is therefore high, but no such drugs exist. The Solution Novel structure-based design of agonistic and antagonistic antibodies for Robo receptors. The Commercial Benefit Anti-Robo antibodies can be used…
Read More
Leishmaniasis is a vector-borne tropical disease that affects 88 countries worldwide. The causal agent is a parasitic protozoon, Leishmania ssp. Cutaneous leishmaniasis (CL), caused by L. major, L. mexicana, and visceral leishmaniasis caused by L. donovani, is one of the most important neglected tropical diseases. Available treatments are highly toxic, and the serious side effects…
Read More
Protein misfolding and aggregation is the fundamental cause of more than 20 amyloidogenic diseases affecting either the central nervous system or a variety of peripheral tissues. These conditions include Alzheimer’s, Parkinson’s, and Huntington’s diseases, and type II diabetes. For Alzheimer’s disease (AD), the oligomerization of amyloid-beta (Aβ) and tau to soluble oligomers and their accumulation…
Read More
The Problem Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) are leading causes of blindness in the Western world. Both are characterized by pathological angiogenesis in the various eye structures. Current treatment for AMD and DR includes monthly intraocular injection of various anti-VEGF agents. Novel biological drug family based on nucleic acid-based ligands, aptamers, is…
Read MoreLicensing
BIRAD grants exclusive and non-exclusive licenses for the commercialization of BIU-based research findings, both to established companies and to new startup ventures established around University technology.
The licenses are granted for specific patents and/or know-how and are limited to a specific field and/or specific products. Licenses include diligence milestones for the development and sale of products covered by the license – to avoid technology "shelving" – and typically include a combination of the following forms of consideration: royalties, milestone payments, upfront fees, equity and/or annual license fees.
Birad's team is ready to assist you :
Nati Fisher
Dr. Iris Haas
Dr. Assaf Sagiv
